In the private equity (PE) healthcare playbook, there is a silent killer of exit multiples: the execution gap. For years, the formula for value creation was simple: buy, build, and scale volume. However, in an era of high interest rates, chronic staffing shortages, and aggressive payer shifts, volume alone will not secure a 12x multiple. Today, the most potent source of operating leverage is not found in the front office or through clinical expansion. It is hidden in the backend revenue cycle.
Revenue cycle management (RCM) is being viewed as a defensive cost center. For a portfolio leader, a high-performing RCM is the ultimate weapon for revenue protection. Not only that, it is also a lever that allows you to expand EBITDA without adding a single unit of headcount or a dollar of marketing spend.
The Hidden Revenue Leakage: A Systemic Valuation Problem
Healthcare revenue leakage is not an atmospheric inefficiency. It is a mechanical failure of execution. When a PE firm acquires a mid-market provider group, they are often unknowingly inheriting a massive pile of abandoned cash.
The "Math of Failure" currently defining the sector looks like this:
- The Denial Trap: The average group faces an 18.7% denial rate, yet administrative burnout ensures that approximately 65% of those claims are never reworked.
- The Underpayment Leak: 11% of claims are systematically underpaid by payers, but roughly 90% of those discrepancies are never disputed.
- The AR Rot: 32% of accounts receivable (AR) age beyond 90 days, and without AI automation intervention, about 70% of that aged AR is eventually written off.
This is a direct erosion of EBITDA. If a portfolio company is ignoring 11% of its earned revenue through underpayments, it is not just losing money; it is suppressing its own valuation.
Data Validation: The Cost of the Status Quo
This is not just anecdotal. Recent KFF analysis confirms that payers are increasingly using automated engines to deny claims at scale. This creates a technological arms race that manual billing teams cannot win. Furthermore, industry reports that RCM staffing turnover has reached a tipping point (33%). This makes it mathematically impossible for human teams to close the execution gap.
How does RCM impact EBITDA in healthcare?
Operating partners must reframe their RCM private equity strategy. Unlike patient volume, which depends on market demand, or reimbursement rates, which depend on payer negotiations, the revenue cycle is an internal mechanism you can control.
Optimizing this mechanism provides a portfolio-wide value creation opportunity that:
- Decouples Revenue from Labor: Increases collections without increasing the billing headcount.
- Protects the Multiple: Turns aged AR into realized cash, which smooths out the balance sheet for exit.
- Institutionalizes Yield: Protects the asset from the knowledge wipeout that occurs when a senior biller leaves.
ANKA: The Execution Layer for Portfolio Excellence
To fundamentally improve EBITDA healthcare metrics, organizations must move beyond Level 1 and Level 2 RCM solutions that just inform or recommend. They merely highlight problems for a human to do list. Instead, firms must embrace Level 3 execution, where claims are autonomously worked through to resolution for revenue recovery, with human intervention only when it's needed.
ANKA is not a dashboard that informs or recommends. It is an execution layer. It sits on top of your existing systems to autonomously resolve the backend RCM work that humans do not have time for. It does not just detect a denial. It writes the appeal, pulls the clinical evidence, and submits it for recovery. It does not just flag an underpayment. It disputes it until the check arrives. It does not just provide AR status; it prioritizes your AR and follow-up with your payers to expedite cash realization.
From Dashboards to Autonomous Action
The Dashboard
Tells you the problem.
The Recommendation
Tells you what to do.
The Execution Layer
Does the work — submitting, tracking, recovering.
The impact on portfolio value is quantifiable:
- 35 to 50% increase in total collections by working 100% of the denial queue.
- 50% lower cost to collect, which significantly boosts margin.
- 60% reduction in 90+ day AR, accelerating cash flow.
EBITDA leakage today vs. autonomous execution tomorrow
Turning Unworked into Valuation
For a PE firm, the goal is predictability and exit readiness. By converting unworked denials, undetected underpayments, and aged AR into realized cash, ANKA provides a standardized performance floor across even the most fragmented portfolios.
Stop guessing how much earned revenue your portfolio companies are leaving on the table. Get a Free Revenue Leakage Assessment. We will run a diagnostic on your unworked denials and aged AR to show you exactly where your execution gap is costing you enterprise value.